Whitehawk Therapeutics, Inc.
WHWK
Positions held
Your positionsWHWK isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $197.82M | Enterprise value | $7.84M | Trailing P/E | — | Forward P/E | -3.51 |
| PEG | — | Price / book | 1.41 | Beta | 0.91 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -45.0% | ROA | -28.7% | Debt / equity | — |
| Current ratio | 17.38 | Free cash flow | -$43.61M | Analyst recommendation | buy | Mean target | $7.71 |
| 52w high | $5.50 | 52w low | $1.87 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$16.6M | -$22.2M | -$23.3M | -$17.7M | -$52.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Operating income | -$18.1M | -$23.5M | -$24.9M | -$19.5M | -$54.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | — |
| Op margin | -1601.1% | -249.5% | -295.4% | -387.5% | — |
| Net income | -$20.6M | -$63.7M | -$65.8M | -$60.5M | — |
| Gross margin | 89.4% | 88.4% | 88.5% | 91.2% | — |
| Gross profit | $6.4M | $23.0M | $21.5M | $13.9M | — |
| Operating income | -$114M | -$64.8M | -$71.9M | -$59.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
2026-10-01 · Stifel Initiates Whitehawk Therapeutics at Buy With $9 Price Target
2026-09-10 · Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
2026-08-28 · What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
2026-08-26 · Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
2026-08-06 · Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
2026-07-21 · Akari Therapeutics, Whitehawk Therapeutics Collaborate to Develop ADC Cancer Treatments
2026-07-21 · Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Price (daily)
Full chart · RSI · MACD · patterns